BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 8837563)

  • 1. Aortic counterpulsation may improve late patency of the occluded coronary artery in patients with early failure of thrombolytic therapy.
    Kono T; Morita H; Nishina T; Fujita M; Onaka H; Hirota Y; Kawamura K; Fujiwara A
    J Am Coll Cardiol; 1996 Oct; 28(4):876-81. PubMed ID: 8837563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Komjathy SF; Poulton J; Stafford JL; Godard J
    Circulation; 1994 Jan; 89(1):361-5. PubMed ID: 8281671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
    J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
    Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
    Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction.
    Zahger D; Karagounis LA; Cercek B; Anderson JL; Sorensen S; Moreno F; Shah PK
    Am J Cardiol; 1995 Oct; 76(11):749-52. PubMed ID: 7572648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction.
    White HD; Cross DB; Elliott JM; Norris RM; Yee TW
    Circulation; 1994 Jan; 89(1):61-7. PubMed ID: 8281696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects on high resolution electrocardiogram of coronary angioplasty in acute myocardial infarct].
    Bruna C; Vado A; Rossetti G; Racca E; Steffenino G; Dellavalle A; Ribichini F; Ferrero V; Uslenghi E
    G Ital Cardiol; 1997 Nov; 27(11):1144-52. PubMed ID: 9463058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
    Lincoff AM; Topol EJ; Califf RM; Sigmon KN; Lee KL; Ohman EM; Rosenschein U; Ellis SG
    Am J Cardiol; 1995 May; 75(14):871-6. PubMed ID: 7732992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: a multivariate analysis.
    de Chillou C; Riff P; Sadoul N; Ethevenot G; Feldmann L; Isaaz K; Simon JP; Boursier M; Khalifé K; Thisse JY; Aliot E
    J Am Coll Cardiol; 1996 Jun; 27(7):1662-8. PubMed ID: 8636551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
    Lundergan CF; Reiner JS; McCarthy WF; Coyne KS; Califf RM; Ross AM
    J Am Coll Cardiol; 1998 Sep; 32(3):641-7. PubMed ID: 9741505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction.
    Agati L; Voci P; Hickle P; Vizza DC; Autore C; Fedele F; Feinstein SB; Dagianti A
    J Am Coll Cardiol; 1998 Feb; 31(2):338-43. PubMed ID: 9462577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent impact of thrombolytic therapy and vessel patency on left ventricular dilation after myocardial infarction. Serial echocardiographic follow-up.
    Popović AD; Nesković AN; Babić R; Obradović V; Bozinović L; Marinković J; Lee JC; Tan M; Thomas JD
    Circulation; 1994 Aug; 90(2):800-7. PubMed ID: 8044951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
    Purvis JA; McNeill AJ; Siddiqui RA; Roberts MJ; McClements BM; McEneaney D; Campbell NP; Khan MM; Webb SW; Wilson CM
    J Am Coll Cardiol; 1994 Jan; 23(1):6-10. PubMed ID: 8277097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
    Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. GUSTO-1 Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Ross AM; Lundergan CF; Rohrbeck SC; Boyle DH; van den Brand M; Buller CH; Holmes DR; Reiner JS
    J Am Coll Cardiol; 1998 Jun; 31(7):1511-7. PubMed ID: 9626828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of early accelerated dose tissue plasminogen activator on in-hospital patency of the infarcted vessel in patients with acute right ventricular infarction.
    Giannitsis E; Potratz J; Wiegand U; Stierle U; Djonlagic H; Sheikhzadeh A
    Heart; 1997 Jun; 77(6):512-6. PubMed ID: 9227293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.